PP
NVIV

Paloma Partners’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Paloma Partners’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-4
Closed -$225K – 2664
2017
Q2 		$225K Buy
+4
New +$218K ﹤0.01% 1950

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Paloma Partners's NVIV Position: Q3 2017 in Review

Paloma Partners sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2017, closing a stake of 4 shares — an estimated $225K sold.

Paloma Partners first reported a position in NVIV in Q2 2017 and held it in 1 quarter. The position peaked at $225K in Q2 2017. 33 funds tracked by Wall St. Rank hold NVIV as of Q3 2017.

  • Paloma Partners reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 4 InVivo Therapeutics Holdings Corp shares in Q3 2017, an estimated $225K.
  • Paloma Partners first reported a position in InVivo Therapeutics Holdings Corp in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's InVivo Therapeutics Holdings Corp position peaked at $225K in Q2 2017.
  • 33 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.